Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

December 1, 2023

Study Completion Date

April 1, 2025

Conditions

Adrenocortical Carcinoma

Interventions

DRUG

Camrelizumab

Camrelizumab was administered 200mg iv every 3 weeks, Apatinib was administered 250 mg p.o. qd.

Trial Locations (1)

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors

lead

West China Hospital

OTHER